May 23, 2017 - "Kalina Scott appointed new CFO of Polyphor"

May 19, 2017 - "Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia"

April 24, 2017 - Press release - eccmid

April 12, 2017 - "Polyphor  announces closing of CHF 40 million private financing round"

March 6, 2017 - "Debra Barker Appointed New CMDO of Polyphor"

February 9, 2017 - Polyphor receives CHF 2.3 Million Award from Wellcome Trust

December 12, 2016 - Polyphor achieves milestone in Taisho collaboration

December 7, 2016 - Polyphor achieves milestone and extends R&D collaboration

October 18, 2016 - Giacomo Di Nepi Appointed New CEO of Polyphor

August 10, 2016 - Polyphor and Gilead establish R&D macrocycle drug discovery collaboration.

June 06, 2016 - Polyphor successfully completes clinical Phase I study with POL6014 targeting life threatening lung diseases including cystic fibrosis.

March 23, 2016 - Polyphor announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014.

December 22, 2015 - Polyphor and Boehringer Ingelheim extend macrocyle R&D collaboration.

December 1, 2015 – Polyphor announces extension of R&D collaboration.

September 17, 2015 – Polyphor and Taisho enter into research collaboration on novel drug candidates.

September 15, 2015 – Polyphor is nominated for the Prix SVC Nordschweiz.

September 1, 2015 – Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I

March 17, 2015 – Polyphor appoints new CEO and strengthens executive management team

January 9, 2015Polyphor develops the elastase inhibitor POL6014 for rare lung diseases using PARI Pharma's eFlow® Technology inhalation device

November 12, 2014Polyphor's lead antibiotic POL7080 receives Qualified Infectious Disease Product (QIDP) designation from the FDA.

November 4, 2013 – Polyphor and Roche join efforts to combat multidrug-resistant bacterial infections. German translationFrench translation.

July 31, 2013 – Polyphor achieves first milestone in MacroFinder® collaboration with Boehringer Ingelheim.

June 11, 2013 – Polyphor attracts senior Pharma professionals to strengthen its Board of Directors.

March 4, 2013 – Polyphor announces successful Phase I results for its Pseudomonas selective antibiotic POL7080.

June 12, 2012 – Polyphor and Boehringer Ingelheim announce MacroFinder® collaboration.

July 27, 2011 - Polyphor and Axxam announce EU funded R&D collaboration for the treatment of Type-2 Diabetes.

May 6, 2010 - Polyphor and Novartis announce PEMfinder® collaboration.

April 12, 2010 - Polyphor and Axxam SpA announce ion channel collaboration.

February 19, 2010 - Polyphor discovers a new class of antibiotics with a novel mode of action. New weapon in the fight against multi-drug resistant bacteria published in “Science” (click here for German version).

Polyphor Ltd
Hegenheimermattweg 125
CH-4123 Allschwil
Switzerland
Tel. +41 61 567 16 00
Fax +41 61 567 16 01
info@polyphor.com

Last modified:   20.06.2017